HCWB (HCW Biologics) Float Percentage Of Total Shares Outstanding: 68.54% (As of Jul. 01, 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $4.65
GF Value $43.79
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Float Percentage Of Total Shares Outstanding?

HCW Biologics HCWB -6.81% 39 Float Percentage Of Total Shares Outstanding is 68.54% as of Jul. 01, 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $43.79 (Possible Value Trap). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, HCW Biologics's float shares is 1.10 Mil. HCW Biologics's total shares outstanding is 1.60 Mil. HCW Biologics's float percentage of total shares outstanding is 68.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, HCW Biologics's Insider Ownership is 12.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, HCW Biologics's Institutional Ownership is 6.91%.

HCWB
39GF Score
HCW Biologics Inc HCWB
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

HCW Biologics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=1.10/1.60
=68.54%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 68.54% mean?
HCW Biologics (HCWB) has a Float Percentage Of Total Shares Outstanding of 68.54% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on HCW Biologics and its competitors.
Is HCW Biologics' Float Percentage Of Total Shares Outstanding too high?
HCW Biologics' current Float Percentage Of Total Shares Outstanding is 68.54%. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Float Percentage Of Total Shares Outstanding compare to KAPA and IMNN?
HCW Biologics' Float Percentage Of Total Shares Outstanding of 68.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on HCW Biologics and its competitors. HCW Biologics's current Float Percentage Of Total Shares Outstanding is 68.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.79, compared to a current price of $4.65 — trading 89.4% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 68.54%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Float Percentage Of Total Shares Outstanding is 68.54% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $4.65 is trading 89.4% below its estimated GF Value™ of $43.79. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Float Percentage Of Total Shares Outstanding: 68.54%
  • GF Value™: $43.79 vs. price of $4.65 (89.4% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.65
Price
$43.79
GF Value